DL-Homocysteine (Synonyms: NSC 206252) |
| Catalog No.GC30684 |
An amino acid
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 454-29-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain.
DL-Homocysteine (0.1-0.5 mM) significantly enhances kynurenic acid (KYNA) production in rat cortical slices, and diministes the production of at 3.0, 5.0, and 10.0 mM, with the estimated IC50 of 6.4 (5.5-7.5) mM. DL-Homocysteine dose-dependently inhibits kynurenine aminotransferases I (KATI) activity at concentrations ≥0.2 mM, with an IC50 of 0.566 (0.442-0.724) mM, and the activity of KAT II with IC50 value of 8.046 (5.804-11.154) mM[1].
DL-Homocysteine (1.3 mmol/kg, i.p.) increases KYNA content (pmol/g tissue) from 8.47 ± 1.57 to 13.04 ± 2.86 and 11.4 ± 1.72 in cortex, and from 4.11 ± 1.54 to 10.02 ± 3.08 in rat hippocampus[1].
[1]. DL-Homocysteine, et al. Dual effect of DL-homocysteine and S-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid. J Neurosci Res. 2005 Feb 1;79(3):375-82.
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *